Cargando…

Anti-amyloid therapies work for Alzheimer’s disease

Detalles Bibliográficos
Autor principal:	Hardy, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365829/ https://www.ncbi.nlm.nih.gov/pubmed/37492486 http://dx.doi.org/10.1093/braincomms/fcad204

Ejemplares similares

An anti-amyloid therapy works for Alzheimer’s disease: why has it taken so long and what is next?
por: Hardy, John, et al.
Publicado: (2023)

Responder analyses for anti-amyloid immunotherapies for Alzheimer’s disease: a paradigm shift by regulatory authorities is urgently needed
por: Salemme, Simone, et al.
Publicado: (2023)

Reply: Unblinding in the lecanemab trial in Alzheimer’s disease
por: Hardy, John, et al.
Publicado: (2023)

In vivo Image of Cerebral Amyloid Angiopathy in an Alzheimer's Disease Mouse Model
por: Kim, Jinho, et al.
Publicado: (2015)

Amyloid-based therapies did fail again! It is the right time to change our vision on building block of Alzheimer's disease
por: Mahmoudi, Morteza
Publicado: (2014)

Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
por: Fedele, Ernesto
Publicado: (2023)

The amyloid hypothesis of Alzheimer's disease at 25 years
por: Selkoe, Dennis J, et al.
Publicado: (2016)

Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer’s disease
por: Castello, Michael A, et al.
Publicado: (2014)

Magnesium may be an effective therapy for Alzheimer’s disease
por: Lei, Dao-Yun, et al.
Publicado: (2022)

Are we ready to use anti-amyloid therapy in Alzheimer's disease?
por: Brucki, Sonia Maria Dozzi, et al.
Publicado: (2022)

Amyloid Depositions and Small Vessel Disease in Patients with Cerebral Amyloid Angiopathy: a Case Series
por: Hong, Yun Jeong, et al.
Publicado: (2020)

Can Anti–β-amyloid Monoclonal Antibodies Work in Autosomal Dominant Alzheimer Disease?
por: Imbimbo, Bruno P., et al.
Publicado: (2020)

Anti-amyloid therapies for Alzheimer disease: finally, good news for patients
por: Ramanan, Vijay K., et al.
Publicado: (2023)

If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?
por: Haass, Christian, et al.
Publicado: (2022)

Catastrophe and Alzheimer's Disease
por: Larner, Andrew J
Publicado: (1995)

The Amyloid-β Pathway in Alzheimer’s Disease
por: Hampel, Harald, et al.
Publicado: (2021)

Factors for Prevention of Alzheimer's Disease
por: Ivanova, Stefka, et al.
Publicado: (2023)

Vascular and Alzheimer Disease in Dementia
por: Strandberg, Timo E., et al.
Publicado: (2020)

Reversing Alzheimer's disease dementia with clemastine, fingolimod, or rolipram, plus anti‐amyloid therapy
por: Fessel, Jeffrey
Publicado: (2022)

Bayes analysis supports null hypothesis of anti‐amyloid beta therapy in Alzheimer's disease
por: Richard, Edo, et al.
Publicado: (2021)

Amyloid cast tubulopathy: a unique form of immunoglobulin-induced renal disease
por: Iliuta, I-A, et al.
Publicado: (2016)

Plasmocytoma-Induced Intertriginous Amyloid Purpura
por: Schreml, Stephan, et al.
Publicado: (2013)

Chronic disease: Working together
por: Laidmäe, Virve-Ines
Publicado: (2013)

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2023)

Handgrip Strength in Elderly People with Alzheimer's Disease
por: Leandro-Merhi, Vania Aparecida, et al.
Publicado: (2023)

Lecanemab: A hope in the management of Alzheimer’s disease
por: Thakkar, Nandita, et al.
Publicado: (2023)

Low Levels of Triiodothyronine in Patients with Alzheimer’s Disease
por: Karimi, Fariba, et al.
Publicado: (2011)

Primary Prevention of Alzheimer’s Disease in Developing Countries
por: Kavoor, Anjana Rao, et al.
Publicado: (2015)

Pharmacological aspects of galantamine for the treatment of Alzheimer's disease
por: Kim, Jae Kwang, et al.
Publicado: (2017)

CSF biomarkers for Alzheimer's pathology and the effect size of APOE ɛ4
por: Andreasson, U, et al.
Publicado: (2014)

Unveiling the Potential of Polyphenols as Anti-Amyloid Molecules in Alzheimer’s Disease
por: Kabir, Eva Rahman, et al.
Publicado: (2023)

Amyloid myopathy as the presenting feature of lymphoplasmacytic lymphoma
por: Guduru, Zain, et al.
Publicado: (2017)

A Critique of the Drug Discovery and Phase 3 Clinical Programs Targeting the Amyloid Hypothesis for Alzheimer Disease
por: Karran, Eric, et al.
Publicado: (2014)

Generic amyloid fibrillation of TMEM106B in patient with Parkinson’s disease dementia and normal elders
por: Fan, Yun, et al.
Publicado: (2022)

Anti-TNF Therapy Before Intestinal Surgery for Crohn’s Disease and the Risks of Postoperative Complications
por: Soop, Mattias, et al.
Publicado: (2021)

Optimal anti-amyloid-beta therapy for Alzheimer’s disease via a personalized mathematical model
por: Hao, Wenrui, et al.
Publicado: (2022)

Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease
por: Withington, Charles G., et al.
Publicado: (2022)

Hypoperfusion, Mitochondria Failure, Oxidative Stress, and Alzheimer Disease
por: Aliev, Gjumrakch, et al.
Publicado: (2003)

New pathogenic variations of mitochondrial DNA in Alzheimer disease!!
por: Nia, Samira Sheibani, et al.
Publicado: (2013)

Tau protein as a target for Alzheimer’s disease management
por: Abdalla, Ahmed
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_l9lqp4q377do92ic4d0qeqe816